Dr. Susheel K. Sharma

SUSHEEL K SHARMA 

Ramakrishna Mission Sevashrama 

Kankhal, Haridwar. 

Phone: 7827908086 

Drsharma@blockagereversal.com 


CURRENT MISSION 


Program Director- Integrative cardiology Center

Located at Ramakrishna Mission Sevashrama Kankhal, Haridwar. This is the first Integrative cardiology Center in India. The Integrative  cardiology program harmonizes the cutting-edge modern medicine principles with aggressive lifestyle change  utilizing the transformational wisdom of Yoga to reverse coronary artery disease. 





MEDICAL LICENSE  


ACTIVITIES AND HONORS 

CERTIFICATIONS


EXPERIENCE






MEDICAL TRAINING  

Interventional Cardiology Fellowship. 

Cardiology Fellowship. 

Research Cardiology Fellowship 

Internal Medicine Residency 

Internal Medicine Residency 


EDUCATION AND TRAINING 


ACTIVITIES AND HONORS 


RESEARCH STUDY PARTICIPATION

1. Principal-Investigator - A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the  Effect of Long-term Treatment with BELVIQ (lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular  Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects with Cardiovascular Disease or  Multiple Cardiovascular Risk Factors (CAMELLIA), Eisai, Co, 2014-2017 

2. Principal-Investigator - Phase 3 Multicenter, Double-blind, Randomized, placebo-controlled, Parallel-Group  Evaluation of The Efficacy, Safety, And Tolerability of Bococizumab (PF04950615), In Reducing The Occurrence Of  Major Cardiovascular Events In High-Risk Subjects (SPIRE 1 & SPIRE 2), Pfizer, Inc, 2015-2016. 

3. Principal-Investigator - A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the  Effect of Ticagrelor twice daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients  with Type 2 

Diabetes Mellitus (THEMIS), AstraZeneca, 2014-2017 


4. Sub-Investigator - A Clinical Evaluation of Absorb™ BVS, the Everolimus-Eluting Bioresorbable Vascular Scaffold 

in the Treatment of Subjects with de novo Native Coronary Artery Lesions (ABSORB RCT), Abbott Vascular, 2013- 2014. 

5. Sub-Investigator - A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous  canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP (CANTOS), Novartis, 2012-2014 

6. Sub-Investigator - A Prospective Multicenter Trial to Assess the Safety and Effectiveness of the SYNERGY TM  Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY TM Stent System) for the Treatment of  Atherosclerotic Lesion(s) (EVOLVE II), Boston Scientific, 2012-2014. 

7. Sub-Investigator - Evaluation of XIENCE PRIME ™ or XIENCE V versus Coronary Artery Bypass Surgery for  Effectiveness of Left Main Revascularization (EXCEL), Abbott Vascular, May 2012 – 2014. 

8. Sub-Investigator - A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent  System (PROMUS Element™) for the Treatment of up to two De Novo Coronary Artery Lesions (PLATINUM),  Boston Scientific, 2009-2014 

9. Sub-Investigator - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Ranolazine on  Major Adverse Cardiovascular Events in Subjects with a History of Chronic Angina Who Undergo Percutaneously  Coronary Intervention with Incomplete Revascularization (RIVER-PCI), May 2012 – 2015. 

10. Sub-Investigator - A Prospective, Single-Blind, Randomized Controlled Study to Evaluate the Safety and  Effectiveness of the Tryton Side Branch Stent™ used in Conjunction with a Drug-Eluting Stent Compared to Side  Branch Balloon Angioplasty in Conjunction with a Drug-Eluting Stent in the Treatment of de novo Bifurcation Lesions  Involving the Main Branch and Side Branch within the Native Coronary Circulation. (TRYTON), Tryton Medical, Inc  2011-2014. 

11. Sub-Investigator -0020A Clinical Evaluation of the Medtronic Endeavor® Resolute Zotarolimus-Eluting Coronary  Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries with a Reference Vessel Diameter of  2.25mm to 4.2mm. (RESOLUTE US), Medtronic, 2008-2015 

12. Sub-Investigator - XIENCE™ V Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study.  (XIENCE V), Abbott Vascular, 2008-2013. 

13. Sub-Investigator - A prospective, multi-center, randomized, double-blind trial to assess the effectiveness and safety  of 12 versus 30 months of dual antiplatelet therapy (DAPT) in subjects undergoing percutaneous coronary intervention (PCI) with either drug-eluting stent (DES) or bare-metal stent (BMS) placement for the treatment of coronary artery  lesions. (The DAPT Study), HCRI, 2010-2014. 

14. Sub-Investigator - A U.S. Post-Approval Study of the ION ™ Paclitaxel-Eluting Platinum Chromium Coronary  Stent System. (ION), Boston Scientific, 2011-2015. 

15. Sub-Investigator - A Prospective, Multicenter Single-Arm Trial to Assess the OMEGA™ Coronary Stent System  for the Treatment of a Single De Novo Coronary Artery Lesion. (OMEGA), Boston Scientific, 2011-2014 

16. Sub-Investigator - A Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the  TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions (TAXUS PERSEUS), Boston Scientific, 2007-2014 


INVITED SPEAKER ENGAGEMENTS

 

PUBLICATIONS

1. Sharma SK, Tetter Ken, Khaja F; Role of coronary angioplasty in acute myocardial infarction. Henry Ford Hospital  Medical Journal. 1991; vol 3&4: 236-239. 

2. Silke B, Verma SP, Sharma SK, Baig W, Reynolds G, Grais MA, Jackson NC, Taylor SH: Hemodynamic dose response actions of cicloprolol in LV dysfunction due to ischemic heart disease. Int J Cardiol 1987; 17:127-136. 

3. Taylor SH, Lee PS, Sharma SK, A comparison of doxazosin and enalapril in the treatment of mild and moderate  hypertension. Am Heart J 1986 Dec 116 (6 PT2). 

4. Silke B, Verma SP, Sharma SK, Frais MA, Reynolds G, Taylor SH. Comparative effects of atenolol and cicloprolol  in cardiac performance in coronary heart ds. J Cardiovasc Pharm. 1989 Jan: 13 (1) 155-61. 

Abstracts: 

1. Sharma SK, Silke B, Verma SP, Reynolds G, Taylor SH. Hemodynamic dose-response effects of intravenous  diltiazem in coronary artery disease. Proc Xth World Congress of Cardiology, Washington, 1986; 2857A. 

2. Silke B, Sharma SK, Verma SP, Reynolds G, Midtbo K, Taylor SH: A hemodynamic and radionuclide assessment of  diltiazem in coronary artery disease. Br J Clin Pharmac 1987; 23:165-b172. 

3. Jackson N, Frais JMA, Sharma SK, Reynolds G, Taylor SH: A dose-response and hemodynamic study of  dopexamine vs. Dopamine in ischemic left ventricular failure. Proc Xth World Congress of Cardiology, Washington,  1986;2302A. 

4. Silke B, Verma SP, Reynolds G, Sharma SK, Taylor SH: A hemodynamic and radionuclide assessment of celiprolol  in coronary artery disease. Proc Xth World Congress of Cardiology, Washington, 1986;792A.